肿瘤细胞治疗研究
英文原题：Tailored approaches in mantle cell lymphoma: refining treatment paradigms with an expert panel opinion.
Tailored approaches in mantle cell lymphoma: refining treatment paradigms with an expert panel opinion.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
套细胞淋巴瘤（MCL）是一种罕见且侵袭性强的非霍奇金B细胞淋巴瘤亚型，在临床管理方面面临重大挑战。近年来治疗策略的进展，如Bruton酪氨酸激酶抑制剂（BTKi）、CAR-T 细胞疗法以及无化疗方案，已改变了治疗格局。这篇专家意见文章基于全球14位专家的见解，探讨了自体干细胞移植（ASCT）在MCL管理中不断演变的作用，以及不适合ASCT患者的治疗策略。文章讨论了新兴疗法的获益与局限性，强调通过个体化治疗策略来优化临床结局。根据患者个体特征制定策略，综合考虑遗传标志物、合并症和区域医疗资源，至关重要。不断演变的MCL治疗格局优先考虑个体化诊疗，BTKi已成为不适合ASCT患者有效的一线选择，也是ASCT的有力替代方案。全球合作与知识共享对于推进MCL治疗和确保最佳诊疗至关重要。
Mantle cell lymphoma (MCL) is a rare and aggressive subtype of non-Hodgkin B-cell lymphoma that presents significant clinical management challenges. Recent advancements in treatment strategies, such as Bruton's tyrosine kinase inhibitors (BTKi), chimeric antigen receptor T-cell (CAR-T) therapy, and chemo-free regimens, have transformed the therapeutic landscape. This expert opinion article, based on insights from 14 experts worldwide, explores the evolving role of autologous stem cell transplantation (ASCT) in MCL management, and the treatment approaches for ASCT-ineligible patients.
It discusses the benefits and limitations of emerging therapies, emphasizing personalized treatment approaches to optimize clinical outcomes. Tailoring strategies to individual patient profiles, considering genetic markers, comorbidities, and regional healthcare resources, is crucial.
The evolving MCL landscape prioritizes personalized care, with BTKi emerging as an effective first-line option for ineligible ASCT patients and a robust alternative to ASCT. Global collaboration and knowledge sharing are essential to advance MCL treatment and ensure optimal care.
MEMBER ACCOUNT
登录成功会直接打开下一页。
